Remedica participated at the PharmaSynergy & BioPharmaSynergy 2024, where our team had an exclusive chance to connect with a focused and like-minded audience from over 40 countries.

PharmaSynergy, which took place in London, between 8-9 February, revolved around personalized one-on-one meetings, facilitating connections among global pharma BD & Licensing professionals, enriched by an engaging content-driven agenda.

The conference served as a platform to explore pharmaceutical opportunities for global expansion, licensing, investment, and portfolio enhancement.

Product Portfolio Focus and Types of Assets Discussed:

• Primary, Niche, Branded, and Hybrid Generics
• Value-Added Medicines (VAMs)
• Biosimilars / Specialty, and Hospital Products
• Legacy products
• Orphan drugs (late stage)
• New chemical entities (late stage)
• Reformulations